Stock Report: Horizon Pharma Inc. (HZNP) Report Updated: May 13, 2013 | Print This Page
Report Features:
Stock Analysis
Rating: Monthly View
| A |  |
|
 |
 |
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B | ||||||||||||
| C | ||||||||||||
| D | ||||||||||||
| F | ||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Rating: Weekly View
| This Week: | D  no change |
|---|---|
| Last Week: | D no change |
| Two Weeks Ago: | D no change |
Company Profile
Horizon Pharma, Inc., a biopharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. The company offers DUEXIS for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; and LODOTRA/RAYOS for the treatment of moderate to severe active rheumatoid arthritis in adults when accompanied by morning stiffness. It also develops LODOTRA/RAYOS, which is under Phase 2 clinical trial for the treatment of polymyalgia rheumatica. The company was founded in 2005 and is headquartered in Deerfield, Illinois.
Recent News: Horizon Pharma Inc.
| 2012-10-15 07:53:52 | Horizon Pharma Announces the U.S. Patent and Trademark Office Has Issued a Notice of Allowance With Claims Covering RAYOS(R) (Prednisone) Delayed-Release Tablets |
| 2012-10-10 00:00:00 | Amendment to the SC 13G filing - Form SC 13G/A |
| 2012-10-05 00:00:00 | - Form CT ORDER |
| 2012-10-05 00:00:00 | Statement of beneficial ownership of common stock by certain persons - Form SC 13G |
| 2012-10-01 07:30:00 | Horizon Pharma Announces Completion of Sales Force Expansion |
My Portfolios (View All)
Save your portfolio—or a few for that matter—and check up on your stocks 24/7! Log in here.
Louis Navellier's Portfolios
- Blue Chip GrowthTop blue chips
- Emerging GrowthTop small-caps
- Ultimate GrowthFastest-moving
- Platinum GrowthElite Model Portfolio